BioCentury
ARTICLE | Company News

MedImmune, GenPat77 target deal

September 30, 2004 7:00 AM UTC

MEDI received an exclusive license to a TIRC7 program in preclinical development from GenPat77 (Berlin, Germany). TIRC7 is expressed on T and B cells and is implicated in negative regulation of immune...